Literature DB >> 31566057

Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis.

Soren Jonzzon1, Leena Suleiman1, Andrew Yousef1, Brenda Young2, Janace Hart2, Patrick Peschl3, Markus Reindl3, Kristin L Schaller4, Jeffrey L Bennett5, Emmanuelle Waubant2, Jennifer S Graves2,6.   

Abstract

Limited data exist on isolated optic neuritis in children. We report the clinical features and treatment of pediatric subjects with monophasic and recurrent idiopathic optic neuritis. This retrospective cohort study of patients with isolated optic neuritis identified 10 monophasic and 7 recurrent optic neuritis cases. Monophasic optic neuritis patients were older (mean 13.3 ± 4.22) than those with recurrent idiopathic optic neuritis (9.86 ± 3.63). Females represented 50% of monophasic and 85.7% of recurrent idiopathic optic neuritis cases. Patients with monophasic optic neuritis were less likely to have a bilateral onset than recurrent idiopathic optic neuritis (40% vs 57.1%). Only 1 case had oligoclonal bands in the cerebrospinal fluid CSF. Most recurrent idiopathic optic neuritis cases had evidence of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (5/7). Treatment of recurrent idiopathic optic neuritis cases included intravenous pulse glucocorticosteroids and immunotherapy. We observed differences between recurrent and monophasic idiopathic optic neuritis. Immunosuppression appeared to prevent further relapses in recurrent idiopathic optic neuritis patients. Weaning immunotherapies after several years of quiescence in recurrent idiopathic optic neuritis may be possible, but larger studies are needed.

Entities:  

Keywords:  adolescents; children; epidemiology; neuroimmunology; neuroophthalmology; pediatric; treatment

Mesh:

Substances:

Year:  2019        PMID: 31566057      PMCID: PMC7018758          DOI: 10.1177/0883073819877334

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

1.  Optic neuritis in children: clinical features and visual outcome.

Authors:  K M Brady; A S Brar; A G Lee; D K Coats; E A Paysse; P G Steinkuller
Journal:  J AAPOS       Date:  1999-04       Impact factor: 1.220

2.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Authors:  John J Chen; Eoin P Flanagan; Jiraporn Jitprapaikulsan; Alfonso Sebastian S López-Chiriboga; James P Fryer; Jacqueline A Leavitt; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; W Oliver Tobin; B Mark Keegan; Claudia F Lucchinetti; Orhun H Kantarci; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Yanjun Chen; Gregory VanStavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Paul W Brazis; Jessica Sagen; Sean J Pittock
Journal:  Am J Ophthalmol       Date:  2018-07-26       Impact factor: 5.258

3.  The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-12

4.  Paediatric optic neuritis: factors leading to unfavourable outcome and relapses.

Authors:  Delphine Averseng-Peaureaux; Marie Mizzi; Helene Colineaux; Laurence Mahieu; Maria Carmela Pera; David Brassat; Yves Chaix; Emilie Berard; Kumaran Deiva; Emmanuel Cheuret
Journal:  Br J Ophthalmol       Date:  2017-09-13       Impact factor: 4.638

Review 5.  Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.

Authors:  Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Autoimmun Rev       Date:  2015-12-17       Impact factor: 9.754

6.  Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein.

Authors:  Melania Spadaro; Stephan Winklmeier; Eduardo Beltrán; Caterina Macrini; Romana Höftberger; Elisabeth Schuh; Franziska S Thaler; Lisa Ann Gerdes; Sarah Laurent; Ramona Gerhards; Simone Brändle; Klaus Dornmair; Constanze Breithaupt; Markus Krumbholz; Markus Moser; Gurumoorthy Krishnamoorthy; Frits Kamp; Dieter Jenne; Reinhard Hohlfeld; Tania Kümpfel; Hans Lassmann; Naoto Kawakami; Edgar Meinl
Journal:  Ann Neurol       Date:  2018-09-09       Impact factor: 10.422

7.  International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.

Authors:  Lauren B Krupp; Marc Tardieu; Maria Pia Amato; Brenda Banwell; Tanuja Chitnis; Russell C Dale; Angelo Ghezzi; Rogier Hintzen; Andrew Kornberg; Daniela Pohl; Kevin Rostasy; Silvia Tenembaum; Evangeline Wassmer
Journal:  Mult Scler       Date:  2013-04-09       Impact factor: 6.312

8.  Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Gregory P Owens; Jeffrey L Bennett; Angela Vincent; Marios C Papadopoulos
Journal:  Acta Neuropathol Commun       Date:  2014-03-31       Impact factor: 7.801

9.  Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.

Authors:  Patrick Peschl; Kathrin Schanda; Bleranda Zeka; Katherine Given; Denise Böhm; Klemens Ruprecht; Albert Saiz; Andreas Lutterotti; Kevin Rostásy; Romana Höftberger; Thomas Berger; Wendy Macklin; Hans Lassmann; Monika Bradl; Jeffrey L Bennett; Markus Reindl
Journal:  J Neuroinflammation       Date:  2017-10-25       Impact factor: 8.322

Review 10.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Authors:  S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann
Journal:  J Neuroinflammation       Date:  2018-05-03       Impact factor: 8.322

View more
  1 in total

1.  Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?

Authors:  Joachim Havla; Thivya Pakeerathan; Kevin Rostasy; Ilya Ayzenberg; Carolin Schwake; Jeffrey L Bennett; Ingo Kleiter; Ana Felipe-Rucián; Stephanie C Joachim; Amelie S Lotz-Havla; Tania Kümpfel; Markus Krumbholz; Eva M Wendel; Markus Reindl; Charlotte Thiels; Thomas Lücke; Kerstin Hellwig; Ralf Gold
Journal:  J Neuroinflammation       Date:  2021-05-29       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.